All Drug Discovery articles
-
NewsDual-therapy approach targets TNBC energy supply in preclinical study
A combination of a CD276-targeting antibody-drug conjugate and mitochondria-disrupting gene therapy has demonstrated anti-tumour activity in preclinical models of metastatic triple-negative breast cancer.
-
NewsImmune profiling could help tailor treatment for primary biliary cholangitis
A new review of primary biliary cholangitis reveals how interactions between bile duct epithelial cells and immune populations sustain chronic inflammation, and explores whether mapping individual disease mechanisms could guide more targeted therapies.
-
NewsHidden bacterial compounds reveal potential cancer drug leads
Researchers have discovered a new family of bacterial natural products that bind the cancer-associated enzyme AKR1C3, revealing potential starting points for drug discovery.
-
NewsWhy aptamer cancer therapies are struggling to reach the clinic
Aptamers can recognise cancer-associated targets and deliver drugs directly to tumour cells. So why have so few reached the clinic? A new review examines the barriers to their development.
-
NewsNew insulin assay speeds up GLP-1 drug candidate testing
A newly developed insulin assay reduced testing time from four hours to around one hour in an evaluation of GLP-1 receptor agonist candidates, delivering comparable results to an established method.
-
ArticleScientists are already using AI agents. Most of what they learn goes unpublished.
Dr Raminderpal Singh speaks to Dr Srijit Seal about how AI agents are changing computational drug discovery, the impact on scientists’ daily work and why valuable findings remain unpublished.
-
NewsNew antifungal compound targets resistant fungi without kidney toxicity
Researchers have designed an antifungal compound that targets a molecular feature unique to fungi, showing activity against drug-resistant pathogens while avoiding kidney injury in preclinical studies.
-
ArticleWhat will it take to trust human-relevant models in drug discovery?
Could organ-on-a-chip technology help identify drug failures before clinical trials? Jim Corbett of Emulate discusses the evidence needed to make human-relevant models reliable tools in drug discovery.
-
News3D Cell Painting reveals cancer drug differences missed in 2D
Two cancer drugs appeared almost identical in conventional screening, but a new 3D Cell Painting method exposed striking differences in their effects, raising questions about what 2D models might miss.
-
NewsNew TRPV1 study could change how painkillers are designed
Researchers have found that the TRPV1 pain receptor responds differently to individual stimuli, revealing functional differences that could help inform the development of more selective pain medicines.
-
ArticleEarlier MSA detection could guide alpha-synuclein drug discovery
MSA and Parkinson’s share the same protein pathology, yet MSA progresses far faster. Could earlier detection reveal why and help researchers identify more effective targets for drug discovery?
-
NewsMLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
-
NewsDisrupting cell-wall transport could expose weakness in resistant bacteria
Researchers have identified a weakness in antibiotic-resistant bacteria that could help restore susceptibility to existing treatments by disrupting a lipid carrier essential for bacterial cell-wall synthesis.
-
NewsResearchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
-
NewsSelf-driving labs and advanced cell models feature at ELRIG 2026
From self-driving laboratories to advanced cellular models, ELRIG Drug Discovery 2026 showcases technologies helping researchers generate better data, evaluate drug candidates and improve early discovery.
-
NewsBCAT1 enzyme identified as fibrosis target after heart attack
Researchers at Nagoya University have identified BCAT1, an enzyme involved in proline supply for collagen synthesis, as a potential target for reducing cardiac fibrosis following myocardial infarction.
-
Newsbit.bio launches refined human astrocyte model for neurotoxicity assessment
Cambridge biotech bit.bio has released ioAstrocytes 2.0, a genetically matched human astrocyte model designed to support functional neuroscience research and earlier assessment of seizure liability and neurotoxicity in drug development.
-
NewsPacBio and TychoBio partner to advance AI-driven RNA therapies
PacBio and AI drug discovery company TychoBio are generating full-length RNA datasets from more than 10,000 samples to train AI models and accelerate the development of RNA therapies for rare diseases.
-
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
-
NewsSpeakers announced for Protein Sciences in Drug Discovery 2026 in Stevenage
Three leading scientists in protein science, structural biology and AI will headline the Protein Sciences in Drug Discovery conference at GSK Stevenage in November 2026, exploring advances in AI-driven drug design, native mass spectrometry and membrane protein folding.